Invention Grant
- Patent Title: FGF-2 variants having N-terminal deletions and increased receptor selectivity and methods of use thereof
-
Application No.: US14629019Application Date: 2015-02-23
-
Publication No.: US09862753B2Publication Date: 2018-01-09
- Inventor: Avner Yayon , Eran Rom , Irina Chumakov , Sara Blumenstein
- Applicant: PROCHON BIOTECH LTD. , HEPACORE LTD.
- Applicant Address: IL Ness Ziona IL Ness Ziona
- Assignee: PROCHON BIOTECH LTD.,HEPACORE LTD
- Current Assignee: PROCHON BIOTECH LTD.,HEPACORE LTD
- Current Assignee Address: IL Ness Ziona IL Ness Ziona
- Agency: Brown Rudnick LLP
- Agent Thomas C. Meyers
- Main IPC: C07K14/50
- IPC: C07K14/50 ; A61K38/18 ; A61K38/00
Abstract:
The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 polypeptides comprising a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions comprising same and methods for use thereof.
Public/Granted literature
- US20150322126A1 FGF-2 VARIANTS HAVING N-TERMINAL DELETIONS AND INCREASED RECEPTOR SELECTIVITY AND USES THEREOF Public/Granted day:2015-11-12
Information query
